期刊
JOURNAL OF GENERAL VIROLOGY
卷 91, 期 -, 页码 2216-2220出版社
MICROBIOLOGY SOC
DOI: 10.1099/vir.0.022343-0
关键词
-
资金
- Wellcome Trust
- Bill and Melinda Gates Foundation
- MRC [G0501257] Funding Source: UKRI
- Medical Research Council [G0501257] Funding Source: researchfish
Vaccinia virus (VACV) encodes multiple proteins to evade host innate immunity, including 814, a virulence factor that binds to the inhibitor of kappa B kinase beta (IKK beta) and blocks nuclear factor kappa B (NF-kappa B) activation. 814 shares 95% amino acid identity with the 183 protein encoded by modified virus Ankara (MVA), an attenuated VACV strain being developed as a vaccine vector. To evaluate whether the immunogenicity of MVA might be increased by manipulation of MVA immunomodulatory proteins, the MVA counterpart of B14, protein 183, was characterized. Unlike B14, protein 183 was unstable in eukaryotic cells unless proteasome-mediated protein degradation was inhibited. Furthermore, 183 did not inhibit NF-kappa B activation in response to cytokine stimulation, and did not restore the virulence of VACV strain Western Reserve lacking gene B14R. The instability and non-functionality of 183 are probably explained by a deletion of 6 aa within alpha-helix 6 of the B14 crystal structure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据